TITLE OF EVENT: The reality of ATMP delivery: pharmacy learning and future developments
EVENT LINK: https://www.jpag.org/145
WEB LINK: https://www.jpag.org/
CONTACT: Hon Events Secretary JPAG, firstname.lastname@example.org
Dr Owen Bain - NHS Royal Free Hospital
Anne Black - NHS
David Caulfield - Newcastle Hospitals
Jackie Chappell - King's College Hospital NHS Foundation Trust
Damian Child - Sheffield Teaching Hospital
Amisha Desai - University Hospitals Birmingham NHS Foundation Trust
Hayley Dixey - Senior GCP Inspector MHRA
Ben Doak - National Senior Programme of Care Manager, Innovative Treatments, NHSEI
Dr Nia Evans - University Hospital of Wales
Imran Kausar - Novartis Gene Therapies
Prof Luigi Martini - Royal Pharmaceutical Society
Dr Cathy McKenzie - Kings College Hospital
Lynn Morrison - Greater Glasgow & Clyde
Dr Rachel Palmer - University Hospitals Bristol & Weston NHS Foundation Trust
Ian Rees - MHRA
Dr Ceri Roberts - NHSBT
Dr Justine Scanlan - Head of Specialist Pharmacy Service
Nisha Shaunak - Guys & St Thomas NHS Foundation Trust
John Spoors - Head of Commercial Medicines Policy Analysis, NHSEI
Alice Tam - The Royal Marsden
Prof Neil Watson - Newcastle Hospitals & Director, Northern Alliance Advanced Therapies Treatment Centre (NA-ATC)
Advanced Therapy Medicinal Products (ATMPs) have revolutionised the treatment of some diseases, particularly those which were previously regarded as intractable to treatment and cure. ATMPs are biological medicines and can be defined by four main categories; in-vivo gene therapies, ex-vivo gene therapies, somatic cellular therapies and tissue engineered products.
As increasing numbers of ATMPs are now being seen through clinical trials and acquiring marketing authorisations, NHS pharmacy and clinical teams are now preparing for the delivery of these disruptive medicines on a larger scale.
The Pan UK Pharmacy Working Group for ATMPs is a network of UK Pharmacists and colleagues who are committed to facilitating the consistent implementation of ATMPs using a collaborative approach to the benefit of patients. The group forms part of the NHS Specialised Pharmacy Service and is supported by the Advanced Therapies Treatment Centres (ATTCs) which are aligned to the group’s vision. ATTCs were established to increase patient access to ATMPs and ensure the UK continues to be at the forefront of ATMP manufacture and clinical delivery. Three years on from the original pharmacy meeting with JPAG, this year's event will reflect on the Pan UK Pharmacy Working Group for ATMPs highlights and outputs as well as providing key updates from important stakeholders who contribute to adoption and accelerated access to ATMPs.
This virtual event will inform and educate the audience about hot topics in the ATMP world, such as; NHS implementation challenges, regulatory issues in ATMPs, ATMP Horizon Scanning, Commissioning of ATMPs – training and work force implications for pharmacy. Breakout sessions for ATMP naïve sites, ATMP experienced sites, Clinical Trials and preparation of ATMPs will form part of the full day symposium. This will provide a forum for networking and discussions through Q&As and by opening channels of communication.
This exciting virtual conference will appeal to pharmacy colleagues from all sectors including Hospital Chief Pharmacists, Clinical Pharmacy, Clinical Trials , Hospital Research & Development Sponsors, Technical Services Colleagues and will provide insight for industry colleagues too.
The event has been kindly sponsored by the Northern Alliance Advanced Therapy Treatment Centre and as such will be free to bona fide NHS delegates on a first come first served basis.